Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus

Xencor (XNCR) Tops Q4 EPS Expectations

March 7, 2016 4:14 PM EST

Xencor (NASDAQ: XNCR) reported Q4 EPS of $0.19, $0.49 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.8 million, versus $5.7 million reported last year.

For earnings history and earnings-related data on Xencor (XNCR) click here.

... More